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a  b  s  t  r  a  c  t
This  study  describes  a  fundamental  functional  difference  between  the two  main  polymorphisms  of  the
pro-form of brain-derived  neurotrophic  factor  (proBDNF),  providing  an  explanation  as  to  why  these  forms
have such  different  age-related  neurological  outcomes.  Healthy  young  carriers  of the  Met66  form  (present
in ∼30%  Caucasians)  have  reduced  hippocampal  volume  and  impaired  hippocampal-dependent  memory
function,  yet  the  same  polymorphic  population  shows  enhanced  cognitive  recovery  after  traumatic  brain
injury,  delayed  cognitive  dysfunction  during  aging,  and  lower  risk  of  late-onset  Alzheimer’s  disease  (AD)
compared  to  those  with  the  more  common  Val66  polymorphism.  To  examine  the  differences  between  the
protein  polymorphisms  in structure,  kinetics  of  binding  to proBDNF  receptors  and  in vitro  function,  we
generated  puriﬁed  cleavage-resistant  human  variants.  Intriguingly,  we  found  no statistical  differences
in  those  characteristics.  As anticipated,  exogenous  application  of proBDNF  Val66  to rat  hippocampal
slices  dysregulated  synaptic  plasticity,  inhibiting  long-term  potentiation  (LTP)  and  facilitating  long-term
depression  (LTD).  We  subsequently  observed  that this  occurred  via the  glycogen  synthase  kinase  3
(GSK3)  activation  pathway.  However,  surprisingly,  we found  that  Met66  had  no such effects  on  either
LTP  or  LTD.  These  novel  ﬁndings  suggest  that,  unlike  Val66,  the Met66  variant  does  not facilitate  synapse
weakening  signaling,  perhaps  accounting  for its protective  effects  with  aging.
©  2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
The neurotrophin brain-derived neurotrophic factor (BDNF) is
ﬁrst translated as the precursor form, proBDNF. A common single
nucleotide polymorphism (SNP) rs6265 at codon 66 in the pro-
domain of human proBDNF changes the amino acid sequence from
the canonical sequence of valine (Val66) to methionine (Met66).
Whilst generally less prevalent, the Met66 polymorphism can be
found in ∼50% Asians, ∼30% Caucasian and ∼4% African–Americans
[1]. Interestingly, population studies show healthy young adult
Met66 carriers to have a signiﬁcant volumetric reduction in spe-
ciﬁc brain structures including the hippocampus [2–4] and are
1 These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.phrs.2015.12.008
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known to suffer from hippocampal-dependent memory deﬁcits
[2,5]. Intriguingly however, studies also show a slower overall
cognitive decline with increasing age in healthy proBDNF Met66
carriers [4–7] compared with Val66. Furthermore, Met66 carriers
have increased recovery of high order executive functioning [8]
and general cognitive functions [9] after traumatic brain injury.
Accordingly, evidence would suggest that Met66 confers some neu-
roprotective effects that are not present with Val66. Exactly why
this is the case and the mechanisms responsible, however, remain
to be fully explained.
BDNF mediates neurotrophic functions including neuronal sur-
vival and differentiation, mainly via its speciﬁc receptor, tyrosine
kinase B (TrkB) [10,11]. In contrast, studies have shown that
the common proBDNF Val66 predominantly facilitates unfavor-
able signaling such as growth cone collapse [12,13], reduction in
spine density [14,15] and apoptosis [14,16–19] through its pan-
neurotrophin receptor (p75NTR) and its co-receptors sortilin or
the sortilin-related VPS10 domain family member SorCS2. Synaptic
plasticity, widely considered to be a cellular correlate for learning
and memory in the brain, is also differentially regulated by BDNF
and proBDNF Val66; whilst BDNF is important in the induction
of long-term potentiation (LTP) and synapse strengthening [20],
by contrast, proBDNF Val66 facilitates long-term depression (LTD)
and the degradation of synapses [15,21]. Accordingly, proBDNF
Val66 appears to directly modulate synapse function by promot-
ing synapse weakening. The relationship between proBDNF Met66
and synapse function, however, remains to be fully characterized.
Earlier studies showed that the presence of one Met66 allele
is sufﬁcient to impair trafﬁcking of the proBDNF Met66 variant
to the distal dendrites, leading to a reduction in both activity-
dependent secretion and synaptic targeting of BDNF-containing
vesicles in neurons [2,22,23]. Indeed, in vitro electrophysiological
studies of Met66 homozygous knock-in mice showed a selective
impairment in activity-dependent synaptic plasticity [24]. How-
ever, these changes seen in Met66 mice could be attributed to the
reduced hippocampal BDNF levels associated with this polymor-
phism [25], and it is yet to be determined whether these observed
impairments are actually due, instead, to differences in binding to
the receptors p75NTR [16], sortilin [21] and SorCS2 [12] and/or
intracellular neuronal signaling induced by the proBDNF Val66 and
Met66 variants.
The present study aimed to analyze and compare the struc-
ture of the proBDNF variants, their receptor binding dynamics,
neuronal intracellular signaling, and capacity to regulate LTP and
LTD. Although previous studies have examined the Met66 vari-
ant in knock-in mice [24], here we puriﬁed two cleavage-resistant
human proBDNF variants and used the proteins in exogenous
application assays. Doing so allowed us to exclude any potential
endogenous differences in protein secretion and indirect BDNF sig-
naling, as well as avoid possible unknown genetic factors present
in knock-in models. Constructs of proBDNF were produced in their
non-glycosylated forms in Escherichia coli. Others [14] report no
functional difference between proBDNF obtained from baculovirus
and E. coli.  Even though we cannot completely exclude the inﬂu-
ence of post-translational modiﬁcations on protein structure and
function, in this study the Val66 and Met66 polymorphisms were
expressed, puriﬁed and treated identically throughout and are
compared on this basis.
2. Methods
2.1. Sub-cloning of proBDNF expression constructs
Human proBDNF DNA constructs were produced as proteolyt-
ically cleavable wild-type (WT) and furin cleavage-resistant (FCR)
forms: (with mutation for FCR): 127RR128 to 127AA128, numbering
as for human proBDNF canonical isoform 1 (ExPASy bioinformat-
ics protein identiﬁer, P23560-1). ProBDNF Met66 was  formed from
Val66 DNA construct by site directed mutagenesis (QuikChange®
Site-Directed Mutagenesis Kit, Stratagene). Genomic DNA was used
as a template to generate proBDNF constructs without the signal
sequence and devoid of extraneous tags. Sub-cloning was  into pET
24a(+) (Novagen) with transformation into XL1-Blue E. coli (Strata-
gene).
2.2. ProBDNF protein expression, refolding and puriﬁcation
ProBDNF expression was performed with modiﬁcations to the
method previously described for proNGF [26], pET 24a(+) plas-
mids encoding for proBDNF WT  and FCR were transformed into
BL21 (DE3) RIPL E. coli (Stratagene). ProBDNF expression was
induced using 1 mM IPTG (isopropyl -D-1-thiogalactopyranoside)
and cells grown for 3 h at 37 ◦C and then harvested by centrifu-
gation. ProBDNF, expressed in inclusion bodies, was isolated by
cell lysis using an X-press (Nike hydraulics, Sweden). The inclusion
bodies were washed in 100 mM Tris buffer (pH8.0) containing in
succession, 100 mM NaCl and 2.5% (v/v) protease cocktail inhibitor
(Sigma # P2174), 1 M NaCl, 1% Triton X-100 and ﬁnally 100 mM
NaCl. Inclusion bodies were solubilized and puriﬁed with mod-
iﬁcations to the previously described method for proNGF [27].
Solubilization was carried out in 6 M guanidine hydrochloride con-
taining 50 mM dithiothreitol (DTT), 50 mM Tris pH8.0 and 1 mM
EDTA. The solubilized proteins were refolded by rapid dilution into
100 mM Tris pH8.5, 750 mM l-arginine, 5 mM EDTA, 5 mM reduced
glutathione and 2 mM oxidized glutathione; samples were then
incubated for 4 h at 10 ◦C. This was dialyzed against buffer contain-
ing 50 mM sodium phosphate pH7.2, 1 mM EDTA and 0.05% (v/v)
protease cocktail inhibitor at 4 ◦C.
2.3. TrkB immunoglobulin-like domain 2 (TrkBIg2) protein
expression and puriﬁcation
TrkBIg2 was expressed, puriﬁed and refolded as previously
described [27].
2.4. Preparation of lysates, sodium dodecyl sulfate
polyacrylamide electrophoresis (SDS PAGE) analysis and western
blotting
Hippocampi pre-incubated with proBDNF were microdissected
to isolate the CA1 dendritic-rich region, as previously described
[28], and resolved on SDS PAGE. Primary antibodies were anti-
BDNF N20 (Santa Cruz, #sc-546); anti-phosphoserine 9 GSK3 (Cell
Signaling, #9336); anti-GSK3 (Santa Cruz, #sc-9166); anti-pan
tau (Tau5, Invitrogen #AHB0042); anti-phosphorylated tau (PHF-1,
kindly provided by Professor Peter Davies, Feinstein Institute, NY);
anti--actin (AbCam, #ab6276).
2.5. Acidic native PAGE analysis
BDNF and proBDNF are basic proteins with high iso-electric
points (pI) of 8.5–9.6 and were analyzed on 15% acidic native PAGE
to determine the presence of oligomers and soluble aggregates. Gels
were stained with Coomassie Blue to visualize the bands.
2.6. Furin digestion
Furin cleaves proBDNF speciﬁcally at the dibasic cleavage site
R-X-(K/R)-R [29]. ProBDNF variants in 100 mM 4-(2-hydroxyethyl)-
1-piperazine ethanesulfonic acid (HEPES) pH7.5 and 1 mM CaCl2
buffer were digested with 2 units of furin (New England Biolabs,
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#P8077) at 30 ◦C for 1 h. Samples were resolved on SDS PAGE and
analyzed by western blotting.
2.7. Circular dichroism (CD)
Secondary structures of proBDNF variants were evaluated by
Far-UV (195–260 nm)  CD analysis. Data acquisition was  outsourced
to Department of Chemistry, University of Warwick, Coventry, UK
and was carried out by Dr. Vincent Hall and Professor Alison Rodger
using a Jasco J-815 spectrometer. Spectra were recorded in 0.2 nm
increments at 100 nm/  min  scanning speed with response time of
1 s. Data were acquired using a 1 mm path length cuvette, accumu-
lating eight scans per protein. Mean residue molar CD (; moles
amino acids−1 dm3 cm−1) were plotted as a function of wavelength
(nm).
2.8. Surface plasmon resonance (SPR)
SPR was performed on a Biacore T200 (GE Healthcare), as previ-
ously described [27] to determine the kinetic proﬁles of proBDNF
variants to their receptor binding domains TrkBIg2 [27], p75NTR
extracellular domain (p75NTR ECD) (Sino Biologicals Inc., #3184-
H08H), sortilin luminal domain (LD) (R&D systems, #3154-ST-050)
and SorCS2 LD (R&D systems, #4238-SR-050). The ligands TrkBIg2
(17.8 ± 0.6 fmol/mm2), p75NTR ECD (40.5 ± 1.8 fmol/mm2), sor-
tilin LD (38.8 ± 1.1 fmol/mm2) and SorCS2 LD (32.35 fmol/mm2)
were immobilized on CM5-S Series sensor chips (GE Healthcare,
# BR-1005-30) using the amine-coupling method according to the
manufacturer’s instructions. The proBDNF variants (analytes) at a
range of 0, 0.625, 1.25, 2.5, 5, 10, 20 nM were allowed to ﬂow over
the chip surface in running buffer (10 mM HEPES, 150 mM NaCl,
3 mM EDTA, 0.05% (v/v) surfactant P20 at a ﬁnal pH7.4). Regener-
ation of the chip surface was carried out using 10 mM Glycine pH
1.5. Kinetic analyzes (n ≥ 3) were performed by ﬁtting the kinetic
plots to the Langmuir 1:1 mathematical model using Biacore T200
evaluation software. All data were double-referenced and plotted
as a function of time. Double referencing included subtraction of
the inactive reference surface SPR response units (RU) from the
ligand-analyte RU and subtraction of buffer association SPR RU at
0 nM analyte on the activated ﬂow cell from the ligand-analyte
responses.
2.9. Primary cell culture and lactate dehydrogenase (LDH) assay
Dissociated cortical neurons from CD1 mice embryonic day 16
(E16) were prepared as previously described [30]. Cells were plated
in neurobasal media with B27 supplement at 1.25 × 105 cells/cm2
on poly-d-lysine coated 96-well plates and maintained at 37 ◦C in
a humidiﬁed 5% CO2 incubator until DIV11. Cortical neurons were
incubated in serum free media for 2 h and subsequently treated
with proBDNF variants (0, 0.05–10 nM)  for 18 h at 37 ◦C, and LDH
release measured. Cell culture supernatant was transferred into 96-
well plates and LDH assay reagent (0.2 M Tris pH8.2, 5 mg/ml  lactic
acid and 1.3 mg/  ml  reaction mix  containing 0.35 mg  tetrazolium,
0.09 mg  phenazine methosulfate (PMS) and 0.9 mg  nicotinamide
adenine dinucleotide (NAD)) was added, incubated at 37 ◦C for
10 min  and the absorbance measured using a FLUOstar OPTIMA
plate reader at 485 nm.
2.10. Primary cell culture and JC-1 assay
E16 mouse cortical neurons (DIV11) were used to assess mito-
chondrial membrane potential in response to proBDNF. Cortical
cells cultured in 96-well plates were treated with puriﬁed proBDNF
WT Val66 and Met66 (0, 0.05, 0.1, 1, 5, 10 nM). Each treatment
was carried out in triplicate and the plates were incubated for 18 h
at 37 ◦C. Following incubation, the 96-well plates were processed
by the 5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl benzimidazolylcarbo-
cyanine iodide (JC-1 dye) assay to measure mitochondrial potential.
The relative ﬂuorescence of J-aggregates was  measured using the
FLUOstar OPTIMA plate reader, indicating change in mitochondrial
membrane potential.
2.11. Animals
All procedures involving animals were carried out in accordance
with the UK Animals (Scientiﬁc Procedures) Act, 1986 and associ-
ated guidelines. Male Wistar rats (Charles River, UK) were used to
prepare acute hippocampal slices (P24–26). Rats were housed four
or ﬁve per cage and allowed access to water and food ad libitum. The
cages were maintained at a constant temperature (23 ± 1 ◦C) and
relative humidity (60 ± 10%) under a 12 h light/dark cycle (lights
on from 07:30 to 19:30).
2.12. Slice preparation
Animals were killed by cervical dislocation and decapitation.
Following this, the brain was  rapidly removed and placed into
ice-cold artiﬁcial cerebrospinal ﬂuid (aCSF; continuously bubbled
with 95% O2/5% CO2) containing 124 mM NaCl, 3 mM  KCl, 26 mM
NaHCO3, 1.25 mM NaH2PO4, 2 mM CaCl2, 1 mM MgSO4, and 10 mM
d-glucose. Hippocampi were extracted and transverse hippocam-
pal slices (400 m thickness) were cut using a McIlwain tissue
chopper (Mickle Laboratory Engineering Co.). Following manual
separation, the slices were then submerged in aCSF for a mini-
mum  of 1 h for recovery before experiments commenced. Slices
were pre-incubated with 1 nM proBDNF Val66 or Met66 in 5 ml
aCSF for 90 min.
2.13. Electrophysiology
Following pre-incubation, ﬁeld recordings were measured at
30 ◦C with continuous perfusion with 1 nM proBDNF (3 ml/min).
LTP was  induced by delivering two  tetanic stimuli to the Schaffer
collateral input (CA3-CA1 pathway) of acute hippocampus slices.
NMDAR-dependent LTD was induced by delivering LFS (1 Hz, 900
pulses, 15 min) at the CA3-CA1 pathway [28]. Field excitatory post-
synaptic potentials (fEPSP) were measured in the hippocampal
CA1 region using recording electrodes ﬁlled with 3 M NaCl. The
data acquisition and analysis was performed using WinLTP (www.
winltp.com). Brieﬂy, the slope of the evoked fEPSPs was  measured,
normalized to the pre-conditioning baseline and expressed as a
percentage of baseline. The mean values of ﬁve consecutive record-
ings (EPSPs) were calculated at approximately 60 min  after the
induction of LFS.
2.14. Study approval
All animal experiments were carried out in accordance with
the UK Scientiﬁc Procedures Act, 1986 and associated guidelines;
methods were carried out in accordance with the approved guide-
lines. All experimental protocols were approved by the University
of Bristol Animal Welfare & Ethical Review Body.
2.15. Statistics
Results were analyzed using Graphpad Prism, v4.0 (GraphPad
Software Inc.). All data were given as mean ± standard error of mean
(s.e.m.). Comparisons between two  experimental groups were per-
formed using unpaired t-test (2-tailed). Experimental groups of
more than two  were compared using one-way analysis of variance
(ANOVA) followed by Dunnett’s multiple comparison post-hoc test
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or two-way ANOVA followed by Bonferroni’s post-hoc test. Signiﬁ-
cance was deﬁned as *P < 0.05, **P < 0.01, ***P < 0.001.
3. Results
3.1. No major differences in structure between the proBDNF
Val66 and Met66 variants
BDNF is ﬁrst translated in a precursor form as proBDNF and is
then N-terminally cleaved by proteases such as furin [29], plasmin
[20] and matrix metallo-proteinases [31,32] to form mature BDNF
(∼14 kDa). The proBDNF Val66 and Met66 variants produced in this
study resolved similarly on SDS PAGE, showing comparable molec-
ular weight of ∼26 kDa with >95% purity (Fig. 1a). Furthermore,
acidic native PAGE gels showed the recombinant proteins to be
devoid of oligomerization and aggregation (Fig. 1b) (no aggregation
was seen in the stacking gel; supplementary Fig. S1 showing full
uncut gel and blots) and proteolytic cleavage using furin showed
both cleavage-resistant protein variants to be completely resistant
to furin cleavage (Fig. 1c).
Supplementry material related to this article found, in the online
version, at http://dx.doi.org/10.1016/j.phrs.2015.12.008.
To determine differences in variant structure, analysis was
performed on two fronts: Firstly, in silico predictor of naturally dis-
ordered regions (PONDR), a web-based neural network [33–35] and
secondly in vitro far-UV circular dichroism (CD). The PONDR predic-
tion using the amino acid sequences corresponding to the canonical
human proBDNF Val66 isoform 1, P23560-1 (1–247 amino acids)
and its variant Met66 polymorphism (VAR 004626) showed Met66
to be more disordered in the region surrounding the Val66Met
polymorphism (Fig. 1d). Amino acid residues are predicted here
as disordered when the PONDR output value ≥0.5. Far-UV CD anal-
ysis showed that overall both variants’ spectra had similar shapes
in the far-UV region with a minimum peak at ∼204 nm,  indicative
of a predominant -sheet structure (Fig. 1e). Spectral overlay fur-
ther showed proBDNF Met66 to contain a small increase in negative
ellipticity at ∼222 nm,  the region characteristic for helical proteins.
Thus, limited differences in structure were observed between the
two variants.
3.2. No signiﬁcant difference in receptor binding afﬁnities
between the Val66 and Met66 proBDNF variants
In the context of the present study, it was important to char-
acterize and compare the binding proﬁles and kinetic constants
of the proBDNF variants to their receptors using surface plasmon
resonance (SPR). This would give direct evidence for their com-
parative ability to bind the tyrosine kinase receptor TrkB, p75NTR,
sortilin and SorCS2. Representative SPR sensorgrams are shown
in Fig. 2(a–h) and complete on–off rates and equilibrium dis-
sociation constants (KD) are provided in Table 1. Both variants
bound with similar afﬁnity (KD) as determined by two-tailed t-
test to the extracellular immunoglobulin-like binding domain of
TrkB (TrkBIg2) (Val66: 2.32 ± 0.09 nM,  n = 4; Met66 2.03 ± 0.14 nM,
n = 3; P = 0.780; Fig. 2a and b) and p75NTR extracellular domain
(ECD) (Val66: 2.42 ± 0.18 nM,  n = 5; Met66 2.31 ± 0.22 nM,  n = 5;
P = 0.502; Fig. 2c and d). Binding to sortilin luminal domain
(LD) (Val66: 2.90 ± 0.37 nM,  n = 5; Met66: 3.83 ± 0.84 nM,  n = 6;
P = 0.312; Fig. 2e and f) and SorCS2 LD (KD Val66 2.23 ± 0.21, n = 3;
Met66 2.23 ± 0.30 nM,  n = 3; P = 0.614; Fig. 2g and h) also did not
differ between the variants. Overall, this is suggestive of little or
no difference in the receptor binding afﬁnities, indicating that any
difference in cellular effects these variants cause is likely to be due
to the differing actions of the proteins themselves.
BDNF was used as a control in each case and the results indicate
(see Table 1) that BDNF bound with sub-nanomolar afﬁnity to TrkB
and p75NTR while it bound only with low afﬁnity to sortilin and
SorCS2.
3.3. Signiﬁcant dose related decrease in mitochondrial membrane
potential by both variants but no signiﬁcant change in LDH release
Previously, cell based assays have shown proBDNF Met66 to
bind less well to intracellular sortilin as determined by immu-
noprecipitation [36]. We  were therefore particularly interested
to know whether, in cells, there would be a difference between
Val66 and Met66 variants with regards to pro-neurotrophin medi-
ated apoptosis, which occurs via binding to the extracellular
p75NTR–sortilin receptor complex [37]. It seemed possible that the
age-related resistance to cognitive decline, which has been associ-
ated with the Met66 variant, may  be due to an inability of Met66 to
bind sortilin at the plasma membrane. Thus, an LDH release assay
was initially used to determine the relative effects of the proBDNF
variants on the cell death process in serum deprived mouse cortical
neurons (DIV11), following treatment for 18 h. However, compared
to the untreated serum-deprived cells, treatment with either vari-
ant (0.05–10 nM)  did not show statistically signiﬁcant cell death
(Fig. 1f). One-way ANOVA followed by Dunnett’s multiple com-
parison post hoc test for comparison within group showed that
proBDNF treatment did not affect the release of LDH from cells
(Val66: P > 0.05; Met66: P > 0.05; Fig. 1f). Two-way ANOVA followed
by Bonferroni’s multiple comparison post hoc test for comparison
between groups showed that this was  independent of Val66Met
substitution (P = 0.473).
The effects on change in mitochondrial membrane poten-
tial (m)  were then assessed in serum starved mouse cortical
neurons (DIV11) using the JC-1 assay. Treatment with proBDNF
(0.05–10 nM)  for 18 h showed a signiﬁcant dose related decrease in
mitochondrial membrane potential for both variants as determined
by one-way ANOVA followed by Dunnett’s multiple compari-
son post hoc test (Val66: P < 0.0001; Met66: P < 0.0001; Fig. 1g).
However, statistical analysis using two-way ANOVA followed by
Bonferroni’s post hoc test between the two groups showed the
Val66Met polymorphism was not associated (P = 0.473) with the
reduction in mitochondrial membrane potential. Consistent with
the earlier ﬁndings, these results suggest no major differences in
the fundamental actions of the protein variants.
3.4. Inhibition of LTP and facilitation of LTD by Val66 proBDNF
variant but not Met66 variant
The absence of any substantial difference between the two
proBDNF variants, either structurally or functionally, was  surpris-
ing, especially given the widely reported contrast in their effects
on cognitive function. Since proBDNF is known to facilitate LTD
via p75NTR [21], we  therefore sought to examine if the exoge-
nous application of the proteins had any consequences on synaptic
plasticity, a molecular correlate of learning and memory, in rat
hippocampal slices. Application of 1 nM proBDNF Val66 caused a
signiﬁcant inhibition of LTP (control: 164.9 ± 0.66%, n = 12; Val66:
119.1 ± 0.79%, n = 6; P < 0.001), whereas unexpectedly, no such inhi-
bition was observed when tissue was  exposed to proBDNF Met66
(162.7 ± 1.44%, n = 6; P = 0.290; Fig. 3a. We  also examined the induc-
tion of LTD, as previously investigated [21]. We  delivered a 1 Hz
low-frequency stimulation protocol, known to induce NMDAR-
dependent LTD in juvenile, but not adult, animals [38]. Consistent
with this, LTD was  not induced in untreated control slices from
P24–26 rats (control: 83.80 ± 0.86%, n = 6), but was facilitated in
slices treated with proBDNF Val66 (Val66: 70.11 ± 0.93%, n = 7;
Fig. 3b). We  hypothesized that the facilitation of LTD by Val66
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Fig. 1. Characterization of proBDNF Val66Met FCR polymorphic variants. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
(a) Wild-type (WT) proBDNF or furin cleavage-resistant (FCR) proBDNF Val66Met variants (50 ng) and BDNF (10 ng) resolved with SDS PAGE and western blotted using
anti-BDNF-N20 1:3000. Val* denotes commercial proBDNF Val66-FCR (Alomone labs). ProBDNF variants have a similar molecular weight of ∼26 kDa (unglycosylated) with
high  purity. (b) ProBDNF (∼1 g) resolved on acidic native PAGE gels stained with Coomassie Blue showed no laddering or unresolved proteins, conﬁrming absence of
oligomerization and soluble aggregates. Mature BDNF (∼14 kDa) used as standard. (c) ProBDNF variants (50 g/ml) furin digested 1 h at 30 ◦C, resolved on 12% SDS  PAGE
and  analyzed using western blotting. Protein bands were detected using anti-BDNF N20 at 1:3000. WT was the positive control, cleaved to mature BDNF. Cleavage-resistant
proBDNF variants were intact following furin exposure. (d) Overlay of PONDR outputs of Val66 and Met66. Values are predicted and scaled 0–1. The thick black line (‘disorder
bar’)  denotes strength of disorder prediction. (e) ProBDNF variants (∼0.1 mg/ml) were measured by CD in the far-UV range. Spectra of both variants showed predominant
-structure with subtle differences in the 222 nm region. Lines show Val66 in light blue Met66 in dark blue. (f) and (g) E16 cortical neurons (DIV11) were serum starved for
2  h and treated with a range of concentrations (0–10 nM)  of proBDNF variants for 18 h, after which cells were processed and measured at (f) 485 nm for LDH release (ProBDNF
FCR  Val66 in light blue, Met66 in dark blue) or (g) at excitation/emission 560/595 nm for JC-1 assay with relative ﬂuorescence of J-aggregates measured (ProBDNF WT  Val66
in  light blue, Met66 in dark blue). The polymorphism was not associated (P = 0.473) with the reduction in membrane potential (two-way ANOVA followed by Bonferroni’s
post  hoc test). In (f) and (g) changes are represented as column graphs with subsequent analysis using one-way ANOVA followed by Dunnett’s multiple comparison post hoc
test  for comparison within group. Throughout, error bars denote standard error of mean. Signiﬁcance is denoted as *P < 0.05, **P < 0.01 and ***P < 0.001.
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Fig. 2. ProBDNF variants are similar in their binding to TrkB, p75NTR, sortilin and SorCS2.
Representative sensorgrams are shown for 0–20 nM proBDNF FCR Val66 (a, c, e, and g) and FCR Met66 (b, d, f, and h) binding to their isolated receptor binding domains TrkBIg2,
p75NTR ECD, sortilin LD and SorCS2 LD. Data was  double referenced (RU) and plotted as a function of time. All the kinetic data were ﬁtted to 1:1 Langmuir mathematical
model  and kinetic constants were calculated. KD denotes mean equilibrium dissociation constant. Mean constants for both Val66 and Met66 variants were not statistically
different. Full kinetic constants are given in Table 1.
reﬂected the activation of LTD signaling. However, surprisingly,
exposure to proBDNF Met66 failed to facilitate LTD when com-
pared to the proBDNF Val66 treated slices (95.81 ± 0.58%, n = 7;
Fig. 3b). The differences seen between the variants and the con-
trols were statistically signiﬁcant (one-way ANOVA followed by
Tukey’s multiple comparison post-hoc test, proBDNF Val66 com-
pared to proBDNF Met66 (P < 0.001), proBDNF Val66 compared to
controls (P < 0.001)).
3.5. Val66 proBDNF variant speciﬁcally activates GSK3ˇ
Since activation of glycogen synthase kinase-3 (GSK3),  a
serine/threonine protein kinase, is critical for the induction of
NMDAR-dependent LTD [39], we examined the effect of proBDNF
variants on GSK3 activation. Exposure of hippocampal slices to
proBDNF Val66 resulted in signiﬁcant dephosphorylation of Ser9-
GSK3, a marker of increased kinase activity, when compared to
control levels (control: 100 ± 20.42%; Val66: 27.2 ± 6.74%; n = 4;
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Table  1
Summary of proBDNF receptor binding kinetics.
Kinetic constants of proBDNF binding to its receptors TrkBIg2, p75NTR ECD and sortilin LD were calculated using 1:1 Langmuir mathematical model. All the kinetic constants
are  given as mean ± s.e.m. and kinetic constants were compared using unpaired t-test (2-tailed). n: number of experiments, ka: association rate constant, kd: dissociation
rate  constant and KD: equilibrium dissociation constant. P denotes values from unpaired, two  tailed t-test between KD of Val66 and Met66. None was  signiﬁcant. Values for
individual ka and kd were also non-signiﬁcant. Binding for BDNF was  too low afﬁnity to give accurate measurement for SorCS2.
n (ka ± s.e.m.) × 106 (M−1 s−1) (kd ± s.e.m.) × 10−3 (s−1) (KD ± s.e.m.) × 10−9 (M)  P of KD Val66 vs Met66
TrkBIg2
Val66 4 1.61 ± 0.31 3.67 ± 0.52 2.32 ± 0.09 0.780
Met66 3 1.99 ± 0.47 3.92 ± 0.67 2.03 ± 0.14
BDNF 7 4.57 ± 0.76 2.32 ± 0.43 0.58 ± 0.13
P75NTR ECD
Val66 5 1.88 ± 0.48 3.94 ± 0.87 2.42 ± 0.18 0.502
Met66 5 1.55 ± 0.43 3.25 ± 0.48 2.31 ± 0.22
BDNF 4 4.44 ± 0.68 2.51 ± 0.12 0.62 ± 0.12
Sortilin LD
Val66 5 2.48 ± 0.63 7.46 ± 2.27 2.90 ± 0.37 0.312
Met66 6 1.56 ± 0.37 5.04 ± 0.87 3.83 ± 0.84
BDNF 7 3.80 ± 1.37 21.7 ± 9.01 6.44 ± 1.61
SorCS2 LD
Val66 3 1.79 ± 0.23 4.00 ± 0.84 2.23 ± 0.21 0.614
Met66 3 2.135 ± 0.45 4.53 ± 0.36 2.23 ± 0.30
BDNF 3 Low afﬁnity Low afﬁnity Low afﬁnity
P < 0.05; Fig. 3c; Supplementary Fig. S2 shows full uncut blots).
However, no signiﬁcant increase in GSK3 activation was observed
when slices were exposed to proBDNF Met66 (74.49 ± 19.36%, n = 4;
P > 0.05; Fig. 3c). These effects were independent of a change in total
levels of GSK3 (control: 100 ± 13.13%; Met66: 104.01 ± 19.79%;
Val66: 100.65 ± 24.41%; n = 4; P > 0.05; Fig. 3c). This suggests that
whilst proBDNF Val66 can activate GSK3, the Met66 variant does
not, and may  go some way to explain their differing effects on
synaptic plasticity.
Supplementry material related to this article found, in the online
version, at http://dx.doi.org/10.1016/j.phrs.2015.12.008.
3.6. ProBDNF Val66 variant inhibits LTP via the activation of
GSK3ˇ
To test whether proBDNF might mediate its effects on plas-
ticity via GSK3, we exposed hippocampal slices to proBDNF
after pre-incubation with the GSK3 inhibitor CT-99021, and
tested whether LTP could be induced. Remarkably, CT-99021 pre-
vented the proBDNF Val66-mediated inhibition of LTP (control:
158.35 ± 5.75%, n = 6; proBDNF + CT: 156.10 ± 10.46%, n = 6; Fig. 3e).
This suggests that the actions of proBDNF Val66 on synaptic plas-
ticity are likely mediated through the activation of GSK3.
3.7. Tau phosphorylation induced by Val66 proBDNF variant not
apparent with Met66 variant
The presence of hyperphosphorylated tau protein is a neu-
ropathological hallmark of AD pathology [40]. Interestingly, the
phosphorylation of tau has recently been identiﬁed as a critical
step in hippocampal LTD induction [41]. Given that GSK3 is an
important regulator of tau phosphorylation, we therefore investi-
gated the regulation of phosphorylation of tau by the two proBDNF
variants. We  found that the proBDNF Val66 variant signiﬁcantly
increased tau phosphorylation (control: 100 ± 28.19%; Val66:
244.55 ± 25.95%, P < 0.01) when compared to control (n = 4; Fig. 3d),
whilst the proBDNF Met66 variant had no effect (101.16 ± 29.3%,
P > 0.05 when compared to control, n = 4). Together, these data are
consistent with a speciﬁc effect of the proBDNF Val66 variant on
synaptic plasticity, where GSK3 is activated to cause dysregula-
tion of synaptic plasticity.
4. Discussion
Previous studies have identiﬁed divergent effects in healthy
young and older proBDNF Met66 carriers versus the Val66 homozy-
gous individuals. Young adult Met66 carriers had reduced cognitive
function and hippocampal volume compared with those with Val66
[2–5], whereas the Met66 allele conferred protection against cog-
nitive decline with aging and after traumatic brain injury [6,7,9].
In order to establish whether physical differences between them
could account for their contrasting effects in cognitive function,
these polymorphic proteins were produced as cleavage-resistant
forms and compared directly for the ﬁrst time for differences in
structure, receptor binding kinetics and function. By theoretical
analysis, using PONDR, Met66 was seen to be more disordered
in the region surrounding the polymorphism. Far-UV CD analysis
indicated a predominance of -sheet structure for both, although
Met66 showed a minor difference in a region characteristic for heli-
cal proteins. Neither of these factors affected the resistance to furin
cleavage; both forms were cleavage-resistant.
We then investigated the possible differences in receptor bind-
ing using SPR. The subtle changes seen in CD analysis between
proBDNF Val66 and Met66 were not reﬂected in SPR binding
assays, which showed similar binding afﬁnities for both polymor-
phic variants to their receptors TrkB and p75NTR, most likely as
a consequence of those receptors binding to the mature peptide
of proBDNF. This too may  account for the lack of statistical differ-
ence in binding between the proBDNF polymorphisms at TrkB and
p75NTR. Pertinent to this, a previous mutagenesis study showed
the evolutionarily conserved 103-arginine residue in the mature
region of BDNF to be important for both mature and proBDNF to
bind TrkB [42]. In addition, recently, proBDNF but not its isolated
PRO domain was shown to co-immunoprecipitate with p75NTR
[12], suggesting an interaction through the mature domain of
proBDNF. However, proBDNF is difﬁcult to crystalize due to its dis-
ordered PRO region [12] and its exact binding domains to p75NTR
and TrkB are not elucidated. It is also noted that this binding afﬁnity
of BDNF and proBDNF to its receptors may  not reﬂect all situa-
tions within the neuron due to the formation of p75NTR–TrkB,
p75NTR–sortilin and p75NTR–SorCS2 complexes. However, this
study compares the Val66 and Met66 forms and in this context
there was no difference in binding to individual p75NTR or TrkB
receptors. Taken together, then, we believe this is compelling evi-
dence that the proBDNF variants do not differ signiﬁcantly in
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Fig. 3. ProBDNF Val66 activates GSK3 to mediate effects on synaptic plasticity.
(a)  LTP was induced by delivering 2 tetanic stimuli to the Schaffer collateral input of acute hippocampus slices. Prior to tetanus, slices were pre-incubated (90 min) with 1 nM
proBDNF Val66 and Met66 FCR variants and perfused constantly with appropriate 1 nM variants. Statistical comparison of the mean fEPSPs values, calculated ∼45 min  after
application of tetanus, showed prominent differences between Val66 and Met66 in inhibiting LTP. (b) LTD was  induced using standard LFS protocol of 1 Hz, 900 pulses for
15  min  in rat (P24–26) hippocampal slices. Prior to LFS, slices were pre-incubated (90 min) with 1 nM proBDNF Val66 or Met66 and perfused constantly with 1 nM proBDNF
variants as appropriate. Statistical comparison of mean fEPSPs values calculated approximately 45 min  after application of LFS showed prominent differences between Val66
and  Met66 in facilitating LTD. (c) Western blotting analysis of phosphorylated GSK3 at serine 9 and total levels of GSK3 after incubation with proBDNF variants for 90 min,
n  = 4. (d) Representative western blot showing PHF-1 phosphorylation levels normalized to tau-5 after treatment with proBDNF Val66 or Met66 (1 nM; 90 min). Bar-chart
showed quantiﬁcation of pooled data (n = 4). (e) Quantiﬁcation of LTP levels following 2 tetanic stimuli with proBDNF Val66 in the presence and absence of CT99021 (1 M;
n  = 6). Signiﬁcance (*P < 0.05; **P < 0.01) was determined using one-way ANOVA with Tukey’s multiple comparison post-hoc test, comparing proBDNF-treated groups to
non-treated control groups. Throughout, control experiments were without exposure to proBDNF and error bars denote s.e.m.
terms of fundamental form and mode of action, and therefore any
observed differences in terms of downstream signaling effects of
the proteins is likely to reﬂect speciﬁc actions of the variants at the
functional level.
Because the full-length sortilin receptor, which facilitates the
intracellular trafﬁcking of proBDNF, is not amenable to SPR, it
was necessary to examine the isolated luminal domain in the
present study. Previously, the binding afﬁnity of proBDNF Val66
to its receptor sortilin luminal domain has been reported variably
in the literature [16,43], possibly attributable to the difference in
species, cleavage-resistant mutations and post-translational mod-
iﬁcations. ProBDNF Met66 variant has been reported to bind less
tightly to intracellular sortilin compared to Val66 during biosynthe-
sis and secretion [23,36] although binding afﬁnities have not been
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determined. Here, contrary to our expectations, we found no dif-
ference in the binding afﬁnities of Val66 and Met66 variants to
sortilin using SPR analysis. More recently, SorCS2 has been shown
to be a receptor for proBDNF [12,44]. SPR analysis performed, using
SorCS2 in this study did not detect any difference in proBDNF Val66
or Met66 binding. However, this may  be due to the use of iso-
lated receptor binding domains in SPR rather than the full-length
receptor and/or the role of the presence of p75NTR co-receptor
complexes in proBDNF binding.
In an effort to examine the differential effect of the proBDNF
variants on apoptosis in a neuronal context we used serum deprived
cortical neurons following proBDNF treatment for 18 h. We per-
formed an assay to measure the amount of LDH released into the
culture medium by dying or damaged cells with compromised cell
membrane integrity. Treatment with either polymorphism up to
10 nM did not increase cell death. However, although previous
ﬁndings have shown that proBDNF-induced apoptosis occurs via
binding to sortilin and p75NTR [37], and proBDNF Val66 mediate
cell death has been shown in cultured cerebral ganglionic neurons
[17] and sympathetic neurons [16], the triggering of apoptosis does
not seem to be inevitable in all cells; others found that proBDNF in
hippocampal neurons did not induce apoptosis [14]. ProBDNF has
also been shown to have some protective effects on neurons [42]
making it more difﬁcult to interpret its effects in vitro. Therefore
cortical neurons were tested for changes in mitochondrial mem-
brane potential, a more subtle form of change, after 18 h. Both
variants of proBDNF mediated a reduction in membrane poten-
tial. Thus addition of proBDNF shows that it has a negative effect
on mitochondrial membrane potential, which may  act as a precur-
sor to release of cytochrome C and caspase 3 cleavage, an event
upstream of that assessed by the LDH assay. However, both Val66
and Met66 variants had similar effects, suggesting that this was not
variant speciﬁc.
The possibility that the Met66 variant may  differentially affect
neuronal plasticity was then tested. As expected, using electro-
physiology, the proBDNF Val66 variant was shown to be able to
facilitate LTD. Compared to the untreated control slices the facili-
tation was signiﬁcant but modest at ∼14%. This was in accord with
previous studies performed in mouse hippocampal slices, which
used a murine furin cleavage-resistant proBDNF Val66 [21] and
in mice overexpressing proBDNF Val66 [15]. However, in contrast
with the study by Woo  et al. [21] the data here show that proBDNF
Val66 was also able to inhibit tetanic stimuli-induced LTP. This
apparent contradiction may  perhaps be explained by differences
between the two experimental approaches, the studies by Woo
et al., were performed with mouse proBDNF Val66 cleavage resis-
tant protein coupled to a his-tag, whilst our studies were performed
with human proBDNF cleavage resistant protein without tags, but
with differing incubation time and concentration. However, the
comparable LTD data between the two studies would suggest that
any differences in protein utilized are speciﬁc to LTP not LTD sig-
nalling. The most likely reason is probably therefore the use of rat
hippocampus in this study whereas mouse tissue was  used in the
study by Woo  et al. [21].
Very recently, studies have shown that GSK3 mediated tau
phosphorylation has an important role in LTD [41,45] and is
reported to be dysregulated in cognitive disorders including AD
[46] and a non-pathological model [47]. Furthermore, it has previ-
ously been shown that the impairment of synaptic plasticity in an
AD and PD pathology model was mediated by GSK3 [48,49]. Given
the activation of GSK3 by the proBDNF Val66 variant speciﬁcally,
as shown here for the ﬁrst time, it is proposed that proBDNF medi-
ates its effects on plasticity via GSK3, thus providing a mechanistic
link between proBDNF Val66 and LTP inhibition. Together, the data
presented here suggest that proBDNF Val66 inhibits LTP through
an enhancement of LTD signaling via the GSK3-pTau pathway.
In contrast, we show that proBDNF Met66 has no effect on
the GSK3-pTau signal pathway. Taken together these data pro-
vide a convincing picture of a proBDNF Val66 speciﬁc effect on
hippocampal synaptic plasticity. Here, proBDNF Val66 activates a
GSK3-pTau signaling pathway leading to synapse weakening that
is entirely absent in the presence of the common Met66 variant.
This study further adds to the ﬁndings of Ninan et al. [24],
which showed Met66 knock-in mice to exhibit impaired LTD, by
circumvention of the reduction in acute activity dependent release
of BDNF seen in these mice. Thus the exogenous application of
human proBDNF used in the present study provides new evidence
for the Val66Met polymorphism to have direct functional relevance
in age-related cognitive impairment. This is in conjunction with the
known decrease in the catalytic form of TrkB with age [50] and AD
[51] compared to p75NTR [52] which makes likely an increased role
of LTD in synaptic plasticity with aging and cognitive impairment.
This may  explain a bias towards protection against cognitive deﬁcit
in later life, of proBDNF Met66, with its reduced ability to facilitate
synaptic weakening. This highlights the importance of understand-
ing the activation of synapse weakening signaling in both normal
and pathological aging conditions, and the potential impact this
may  have in the development of novel therapeutic interventions.
5. Conclusion
In order to try to explain the age-related functional differ-
ences seen in carriers of the common Val66Met polymorphism,
the separate human recombinant proteins were produced and the
biophysical, kinetic, cellular and synaptic differences between the
two common proBDNF polymorphisms were assessed. Theoretical
analysis of structure, using PONDR, and analysis of far-UV CD mea-
surement showed only minor structural differences between the
polymorphisms. Neither could the polymorphisms be differenti-
ated in terms of their binding kinetics to receptor binding domains.
Furthermore, in cell assays, both variants caused a similarly signif-
icant dose dependent reduction in membrane potential, although
not in release of LDH in cortical neurons. However, differences were
noted by electrophysiology, in rat hippocampal slices. ProBDNF
Val66 was  able to facilitate LTD and inhibit LTP, whereas Met66
was not. Further analysis revealed that Val66 was able to mediate
its effects on synaptic plasticity via GSK3, this provides the pro-
cess of association between Val66 and LTP inhibition. Thus proBDNF
Val66 may  inhibit LTP by enhancing LTD signaling via the GSK3-
pTau pathway. These data also suggest a possible explanation as to
why Met66 may  confer protection against cognitive deﬁcit in later
life, due to its reduced ability to facilitate synaptic weakening.
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